New drug combo targets Hard-to-Treat cancers

NCT ID NCT06804824

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times

Summary

This early-stage study tests a new drug called VVD-159642, which blocks certain cancer-driving proteins. It is for adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have not responded to other treatments. The study will test the drug alone or with other targeted therapies to find safe doses and see if it shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Research South Australia (CRSA)

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Linear Clinical

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • NEXT Austin

    RECRUITING

    Austin, Texas, 78758, United States

  • NEXT Dallas

    RECRUITING

    Irving, Texas, 75039, United States

  • NEXT San Antonio

    RECRUITING

    San Antonio, Texas, 78299, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • START Mid West

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • START Mountain

    RECRUITING

    Ogden, Utah, 84401, United States

  • START San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.